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Introduction {#sec005}
============

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults, accounting for approximately 20% of newly diagnosed lymphoid neoplasms \[[@pone.0176008.ref001]\]. DLBCL accounts for 31% of all non-Hodgkin's lymphomas (NHL) in Western countries\[[@pone.0176008.ref002]\]. DLBCL is biologically and clinically heterogeneous and is typically treated with an R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) strategy \[[@pone.0176008.ref003]\]. Approximately 60--70% of DLBCL patients are curable using various regimens whereas other patients fail to respond to chemotherapy or have poor long-term survival outcomes \[[@pone.0176008.ref004]\]. Some indexes such as the International Prognostic Index (IPI) and gene expression profiling (GEP) can be used to identify risk patients \[[@pone.0176008.ref005], [@pone.0176008.ref006]\]. However, these parameters either lack the accuracy for prognosis or are hard to obtain in everyday clinical practice. Therefore, simple, inexpensive, and easily available prognostic biomarkers are urgently needed.

Inflammation often already exists in the tumor microenvironment before tumor occurrence and continues to facilitate tumor progression \[[@pone.0176008.ref007], [@pone.0176008.ref008]\]. Systemic inflammatory responses caused by and accompanied by tumorigenesis could provide information for prognostication. A series of prognostic indexes based on laboratory test results have emerged as objective and inexpensive indicators \[[@pone.0176008.ref009]\]. Such parameters include C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and modified Glasgow Prognostic Score (mGPS)\[[@pone.0176008.ref010]--[@pone.0176008.ref015]\], of which, NLR was found to be related with worse survival outcomes in a variety of tumors \[[@pone.0176008.ref016]\], including DLBCL \[[@pone.0176008.ref012], [@pone.0176008.ref013], [@pone.0176008.ref017], [@pone.0176008.ref018]\]. However, previous studies have reported controversial results concerning the prognostic value of NLR in DLBCL \[[@pone.0176008.ref012], [@pone.0176008.ref017]--[@pone.0176008.ref020]\]. The conflicting results may be due to small sample sizes and heterogeneous patients in individual studies. To comprehensively evaluate NLR in DLBCL, a meta-analysis was performed by aggregating data from relevant studies. In this meta-analysis, we investigated the relationship between NLR and overall survival (OS) and progression-free survival (PFS); in addition, we also explored the association between NLR and different clinicopathological factors in DLBCL.

Materials and methods {#sec006}
=====================

This meta-analysis was carried out in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@pone.0176008.ref021]\].

Literature search {#sec007}
-----------------

A systematic literature search was performed by using the databases of PubMed, Embase, Web of Science, and China National Knowledge Infrastructure (CNKI) for all relevant studies. There was no language restriction. The last literature search was updated on February 17, 2017. The following terms were used in the search: "NLR," "neutrophil-lymphocyte ratio," "neutrophil to lymphocyte ratio," "diffuse large B-cell lymphoma," "lymphoma, large B-cell, diffuse" \[MeSH Terms\], and DLBCL. The references in the relevant studies were also screened for possible inclusions.

Selection criteria {#sec008}
------------------

The inclusion criteria were as follows: (a) NLR was obtained from a hematological test before treatment; (b) the diagnosis of DLBCL was pathologically confirmed; (c) the relationships between NLR and survival including OS or PFS were investigated or sufficient data were provided; (d) studies were published as full-text articles in English or Chinese. Literature falling under the following category was excluded: (a) reviews, meeting abstracts, letters, and duplicate studies; (b) irrelevant studies; (c) animal studies; and (d) studies without sufficient data.

Data extraction and qualitative assessment {#sec009}
------------------------------------------

Data were extracted by two independent investigators from eligible studies; discrepancies were resolved by joint discussion. The following information was extracted: first author, year of publication, study location, number of patients, tumor stage, treatment regimens, research period, cut-off value, survival outcomes, and hazard ratios (HRs) and 95% confidence intervals (CIs) for OS and/or PFS. The quality of each study was evaluated by using the 9-star Newcastle-Ottawa Scale (NOS) for cohort studies\[[@pone.0176008.ref022]\]. Studies with scores ≥7 were considered high-quality studies.

Statistical analysis {#sec010}
--------------------

HRs with corresponding 95% CIs were used to evaluate the relationships between NLR and OS and/or PFS in DLBCL. Odds ratios (ORs) with 95% CIs were used to assess the strength of association between NLR and clinicopathological parameters. The heterogeneity among studies was calculated using Cochran's Q test and Higgins I-squared statistic. P for heterogeneity \<0.1 or *I*^2^ \>50% was considered a significant level of heterogeneity. Both fixed effects (Mantel---Haenszel method) and random effects (DerSimonian and Laird method) models were performed to generate the pooled HRs. The random-effects model is more conservative and provides better estimates with wider confidence intervals\[[@pone.0176008.ref023], [@pone.0176008.ref024]\]. Meta-regression was also performed. Sensitivity analysis was conducted by sequential omission of each included studies. Publication bias was tested using Begg's funnel plots. P\<0.05 was considered statistically significant. All statistical analyses were performed with Stata version 12.0 (Stata Corp, College Station, TX).

Results {#sec011}
=======

Literature selection and study characteristics {#sec012}
----------------------------------------------

The flowchart of the literature selection process is shown in [Fig 1](#pone.0176008.g001){ref-type="fig"}. A total of 46 studies were identified through database searching, 33 records were screened after duplicates were excluded. Then, 22 records were excluded after title and/or abstract reading. Subsequently, 11 full-text articles were evaluated for eligibility. Five studies were further excluded because they were meeting abstracts and studies with insufficient or those that did not focus on NLR. Three studies\[[@pone.0176008.ref025]--[@pone.0176008.ref027]\] were found to be eligible through updated searching. In total, 9 studies \[[@pone.0176008.ref012], [@pone.0176008.ref013], [@pone.0176008.ref017], [@pone.0176008.ref018], [@pone.0176008.ref025]--[@pone.0176008.ref029]\] with 2297 patients were included for the meta-analysis. The main characteristics of included studies are demonstrated in [Table 1](#pone.0176008.t001){ref-type="table"}. The studies were published between 2010 and 2017. Sample sizes ranged from 51 to 515. Seven studies\[[@pone.0176008.ref012], [@pone.0176008.ref013], [@pone.0176008.ref017], [@pone.0176008.ref018], [@pone.0176008.ref025]--[@pone.0176008.ref027]\] were published in English and 2 studies \[[@pone.0176008.ref028], [@pone.0176008.ref029]\] were published in Chinese. Eight studies \[[@pone.0176008.ref012], [@pone.0176008.ref013], [@pone.0176008.ref017], [@pone.0176008.ref018], [@pone.0176008.ref026]--[@pone.0176008.ref029]\] investigated the association between NLR and OS and 7 studies \[[@pone.0176008.ref012], [@pone.0176008.ref017], [@pone.0176008.ref018], [@pone.0176008.ref025]--[@pone.0176008.ref027], [@pone.0176008.ref029]\] reported a connection between NLR and PFS. All studies obtained a NOS score of ≥7. The detailed information of quality assessment is shown in [Table 2](#pone.0176008.t002){ref-type="table"}.

![Flowchart of article selection.](pone.0176008.g001){#pone.0176008.g001}

10.1371/journal.pone.0176008.t001

###### Characteristics of included studies.

![](pone.0176008.t001){#pone.0176008.t001g}

  Study       Year   Region    NOS score   Sample size   Age (years) median(range)   Stage   Treatment regimen   Study period   Cut-off   Outcomes analyzed
  ----------- ------ --------- ----------- ------------- --------------------------- ------- ------------------- -------------- --------- -------------------
  Porrata     2010   USA       8           255           64(20--92)                  I-IV    R-CHOP              2000--2007     3.5       OS, PFS
  Ho          2015   Taiwan    9           148           61(16--88)                  I-IV    R-CHOP              2001--2010     4.35      OS, PFS
  Keam        2015   Korea     8           447           61(16--87)                  I-IV    R-CHOP              2003--2010     3         OS, PFS
  Melchardt   2015   Austria   8           515           65(20--92)                  I-IV    R-CHOP              2004--2014     5.54      OS
  Ming        2015   China     7           51            55(20--85)                  I-IV    R-CHOP              2009--2013     2.32      OS
  Hong        2016   Korea     8           313           56(16--86)                  I-IV    R-CHOP              2008--2011     2.42      PFS
  Ni          2016   China     7           57            54(14--75)                  I-IV    R-CHOP              2009--2015     2.915     OS, PFS
  Wang        2016   China     8           156           NR                          I-IV    R-CHOP              2006--2015     3         OS, PFS
  Wang        2017   China     9           355           54(18--86)                  I-IV    R-CHOP              2005--2011     2.81      OS, PFS

OS = overall survival; PFS = progression-free survival; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; NOS = Newcastle-Ottawa Scale, NR = not reported.

10.1371/journal.pone.0176008.t002

###### Newcastle-Ottawa Scale for quality assessment of studies included in the meta-analysis.

![](pone.0176008.t002){#pone.0176008.t002g}

  Study              Selection   Comparability   Outcome   Overall                    
  ------------------ ----------- --------------- --------- --------- ---- --- --- --- ---
  Porrata (2010)     ☆           ☆               ☆         ☆         ☆☆   ☆       ☆   8
  Ho (2015)          ☆           ☆               ☆         ☆         ☆☆   ☆   ☆   ☆   9
  Keam (2015)        ☆           ☆               ☆         ☆         ☆☆   ☆   ☆       8
  Melchardt (2015)   ☆           ☆               ☆         ☆         ☆☆   ☆   ☆       8
  Ming (2015)        ☆           ☆               ☆         ☆         ☆☆   ☆           7
  Hong (2016)        ☆           ☆               ☆         ☆         ☆☆   ☆   ☆       8
  Ni (2016)          ☆           ☆               ☆         ☆         ☆☆   ☆           7
  Wang (2016)        ☆           ☆               ☆         ☆         ☆☆   ☆   ☆       8
  Wang (2017)        ☆           ☆               ☆         ☆         ☆☆   ☆   ☆   ☆   9

NLR and OS, PFS {#sec013}
---------------

Eight studies \[[@pone.0176008.ref012], [@pone.0176008.ref013], [@pone.0176008.ref017], [@pone.0176008.ref018], [@pone.0176008.ref026]--[@pone.0176008.ref029]\] with 1984 patients showed the relationship between NLR and OS in DLBCL. The heterogeneity tests suggested non-significant heterogeneity (*I*^2^ = 7.3%, P~H~ = 0.374; [Table 3](#pone.0176008.t003){ref-type="table"}). The pooled data showed that a high NLR significantly correlated with a worse OS (HR = 1.84, 95% CI = 1.52--2.22, p\<0.001, [Table 3](#pone.0176008.t003){ref-type="table"}, [Fig 2](#pone.0176008.g002){ref-type="fig"}). For further investigation, we conducted subgroup analysis. As shown in [Table 3](#pone.0176008.t003){ref-type="table"}, the results demonstrated that NLR remained a significant prognostic marker regardless of ethnicity (Asian or Non-Asian), sample size (\<200 or ≥200), and cut-off value (NLR ≤3 or NLR \>3). In terms of NLR and PFS, the combined results from 7 studies\[[@pone.0176008.ref012], [@pone.0176008.ref017], [@pone.0176008.ref018], [@pone.0176008.ref025]--[@pone.0176008.ref027], [@pone.0176008.ref029]\] with 1731 patients showed that NLR was also a factor predicting worse PFS in DLBCL (HR = 1.64, 95% CI = 1.36--1.98, p\<0.001; *I*^2^ = 36.9%, P~H~ = 0.147, [Table 3](#pone.0176008.t003){ref-type="table"}, [Fig 2](#pone.0176008.g002){ref-type="fig"}). Subgroup analysis demonstrated that NLR was still a prognostic biomarker regardless of study location, sample size, and cut-off. The results of meta-regression are shown in [Table 3](#pone.0176008.t003){ref-type="table"}.

![Forest plots for the estimate of NLR associated with (A) OS and (B) PFS in the meta-analysis.](pone.0176008.g002){#pone.0176008.g002}

10.1371/journal.pone.0176008.t003

###### Main results of meta-analysis.

![](pone.0176008.t003){#pone.0176008.t003g}

  Outcome   Variables     No. of studies   Heterogeneity   Fixed-effects model   Random-effects model   Meta-regression                                
  --------- ------------- ---------------- --------------- --------------------- ---------------------- ----------------- ------------------ --------- -------
  OS        All           8                7.3             0.374                 1.84(1.52--2.22)       \<0.001           1.85(1.52--2.26)   \<0.001   
            Ethnicity                                                                                                                                  0.424
            Asian         6                0               0.479                 1.98(1.55--2.54)       \<0.001           1.98(1.55--2.54)   \<0.001   
            Non-Asian     2                54.9            0.136                 1.66(1.24--2.22)       0.001             1.72(1.1--2.69)    0.017     
            Sample size                                                                                                                                0.264
            \<200         4                12.5            0.33                  2.37(1.52--3.72)       \<0.001           2.45(1.49--4.02)   \<0.001   
            ≥200          4                0               0.458                 1.74(1.41--2.14)       \<0.001           1.74(1.41--2.14)   \<0.001   
            Cut-off                                                                                                                                    0.326
            ≤3            5                2.9             0.39                  2.04(1.57--2.67)       \<0.001           2.05(1.56--2.7)    \<0.001   
            \>3           3                10              0.329                 1.65(1.27--2.16)       \<0.001           1.67(1.25--2.21)   \<0.001   
  PFS       All           7                36.9            0.147                 1.64(1.36--1.98)       \<0.001           1.69(1.32--2.15)   \<0.001   
            Ethnicity                                                                                                                                  0.059
            Asian         6                0               0.612                 1.5(1.23--1.84)        \<0.001           1.5(1.23--1.84)    \<0.001   
            Non-Asian     1                \-              \-                    2.98(1.78--4.98)       \<0.001           2.98(1.78--4.98)   \<0.001   
            Sample size                                                                                                                                0.564
            \<200         3                0               0.756                 1.88(1.3--2.71)        0.001             1.88(1.3--2.71)    0.001     
            ≥200          4                63.6            0.041                 1.57(1.26--1.95)       \<0.001           1.61(1.11--2.33)   0.011     
            Cut-off                                                                                                                                    0.083
            ≤3            5                0               0.526                 1.47(1.18--1.82)       \<0.001           1.47(1.18--1.82)   \<0.001   
            \>3           2                39.5            0.199                 2.39(1.62--3.51)       \<0.001           2.35(1.43--3.88)   0.001     

NLR and clinicalpathological features {#sec014}
-------------------------------------

We also comprehensively investigated the association between NLR and clinicopathological features. A total of 8 clinicopathological features were investigated, as follows: sex (male vs. female), age (\>60 vs. ≤60 years), European Cooperative Oncology Group performance status score (ECOG PS; ≥2 vs. \<2), Ann Arbor stage (III/IV vs. I/II), lactate dehydrogenase (LDH) level (elevated vs. normal), extranodal disease (≥2 vs. \<2), IPI score (≥3 vs. \<3), and presence of B symptoms (yes vs. no). The results are summarized in [Fig 3](#pone.0176008.g003){ref-type="fig"}. As shown in [Fig 3](#pone.0176008.g003){ref-type="fig"}, NLR was associated with Ann Arbor stage (OR = 2.09, 95% CI = 1.14--3.81, p = 0.017), LDH level (OR = 2.74, 95% CI = 1.16--6.46, p = 0.021), extranodal disease (OR = 1.63, 95% CI = 1.06--2.52, p = 0.027), and IPI score (OR = 2.44, 95% CI = 1.03--5.08, p = 0.043). However, NLR was found to have no significant association with sex (OR = 0.89, 95% CI = 0.71--1.11, p = 0.29), age (OR = 1.18, 95% CI = 0.94--1.48, p = 0.152), ECOG PS (OR = 1.78, 95% CI = 0.71--4.46, p = 0.217), or presence of B symptoms (OR = 1.56, 95% CI = 0.7--3.48, p = 0.278).

![Forest plots for the association of NLR and (A) sex, (B) age, (C) ECOG PS, (D) Ann Arbor stage, (E) LDH level, (F) extranodal disease, (G) IPI score, and (H) presence of B symptoms in meta-analysis.](pone.0176008.g003){#pone.0176008.g003}

Sensitivity analysis {#sec015}
--------------------

Sensitivity analysis was conducted by omitting one study at a time and analyzing the remaining studies. The results are shown in [Fig 4](#pone.0176008.g004){ref-type="fig"}, the results were not substantially changed, showing the reliability and stability of our results.

![Sensitivity analysis for (A) OS and (B) PFS.](pone.0176008.g004){#pone.0176008.g004}

Publication bias {#sec016}
----------------

In this meta-analysis, we introduced Begg's funnel plot to test publication bias. As shown in [Fig 5](#pone.0176008.g005){ref-type="fig"}, the results suggested no significant publication bias for OS (p = 0.063) and PFS (p = 0.133).

![Begg's test for (A) OS and (B) PFS.](pone.0176008.g005){#pone.0176008.g005}

Discussion {#sec017}
==========

Prior studies have suggested that NLR is associated with worse survival outcomes in various cancers \[[@pone.0176008.ref030]--[@pone.0176008.ref035]\]. As for DLBCL, the prognostic role of NLR remains controversial, which may be due to the clinically heterogeneous features of this disease. In the current meta-analysis, we aggregated data from 9 studies including 2297 patients. The results showed that NLR was correlated with poor OS (HR = 1.84, 95% CI = 1.52--2.22, p\<0.001) as well as worse PFS (HR = 1.64, 95% CI = 1.36--1.98, p\<0.001). In addition, in the subgroup analysis stratified by location, sample size, and cut-off value, the prognostic value of NLR remained significant. Furthermore, NLR was also associated with Ann Arbor stage, LDH level, extranodal disease, and IPI score. The findings of this study suggest that NLR is a significant prognostic marker in DLBCL; additionally, because measurement of NLR is easy and inexpensive, NLR has potential to be validated in clinical practice for DLBCL patients.

A number of studies have shown that persistent chronic inflammation could trigger tumorigenesis \[[@pone.0176008.ref007], [@pone.0176008.ref036], [@pone.0176008.ref037]\]. Inflammatory responses could promote angiogenesis and protect cancer cells from immune attacks \[[@pone.0176008.ref036]\]. In the tumor microenvironment, neutrophils secrete a variety of cytokines including interleukin-2, interleukin-10, and tumor necrosis factor α, which further promote cancer development\[[@pone.0176008.ref038]\]. In contrast, lymphocytes are well known to exert dominant roles in immune defense against cancer cells \[[@pone.0176008.ref039]\]. Lymphocytes can induce cytotoxic cell death \[[@pone.0176008.ref040]\]. NLR has a biological rationale because it reflects the strength of immune responses in cancer patients. A variety of meta-analyses have shown the significant prognostic value of NLR in solid tumors including lung cancer\[[@pone.0176008.ref041]\], gastric cancer \[[@pone.0176008.ref042], [@pone.0176008.ref043]\], hepatocellular carcinoma \[[@pone.0176008.ref044]\], breast cancer \[[@pone.0176008.ref032]\], and renal cell carcinoma \[[@pone.0176008.ref030]\]. The results demonstrated that NLR was associated with poor survival in various tumors, which was in accordance with results in this meta-analysis. We also noted that a meta-analysis investigating the correlation between NLR and various solid tumors\[[@pone.0176008.ref016]\]; however, in this meta-analysis, only 1 study regarding Hodgkin's lymphoma \[[@pone.0176008.ref045]\] was included for analysis, and DLBCL was not investigated. To the best of our knowledge, this is the first meta-analysis exploring the prognostic value of NLR in patients with DLBCL. We also noted that previous meta-analyses also showed that absolute lymphocyte count and lymphocyte/monocyte ratio were prognostic markers for DLBCL\[[@pone.0176008.ref046], [@pone.0176008.ref047]\]. Feng et al. revealed that low absolute lymphocytic count has an adverse effect on outcome in DLBCL \[[@pone.0176008.ref046]\]. This finding is in accordance with our results because low absolute lymphocytic count leads to high NLR when the neutrophil count is fixed.

Several limitations need to be pointed out in this study. First, the sample size was relatively small. Only 9 studies were included for analysis, especially for the association between NLR and clinical parameters. The small sample size may introduce bias. Second, cut-off values of NLR were inconsistent in primary studies, which suggests a need for a uniform cut-off value in further studies. Third, publication bias examination was suboptimal in detecting publications when the included studies were fewer than 10\[[@pone.0176008.ref048]\]. Only 9 studies were included in this meta-analysis, although Begg's test suggested no significant publication bias. This could not rule out the possibility of publication bias because insufficient studies were included. Fourth, meta-regression was performed although meta-regression is most suitable for analyses that include \>10 cohorts\[[@pone.0176008.ref049]\]. Eight studies were included for OS and 7 studies were for PFS; therefore, the results of meta-regression need to be treated with caution. Fifth, the confidence intervals for *I*^2^ were not reported, which could be useful for heterogeneity estimates\[[@pone.0176008.ref050]\].

In conclusion, this meta-analysis indicated that elevated NLR correlated with poor OS and poor PFS in patients with DLBCL. In addition, NLR was also strongly associated with Ann Arbor stage, LDH level, extranodal disease, and IPI score. The results suggested that NLR could be recommended as an inexpensive prognostic biomarker in clinical practice for DLBCL. However, due to the limitations mentioned above, further large-scale studies are needed to confirm our results.

Supporting information {#sec018}
======================

###### PRISMA checklist.

(DOC)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: **Conceptualization:** JW XZ.**Data curation:** JW YL.**Formal analysis:** JW YL ZL.**Funding acquisition:** YL XL.**Investigation:** XZ ZL XL.**Methodology:** JW XZ YL.**Project administration:** JW.**Resources:** JW ZL XL.**Software:** JW XZ.**Supervision:** JW XL.**Validation:** JW XZ ZL.**Visualization:** YL ZL XL.**Writing -- original draft:** YL ZL XL.**Writing -- review & editing:** YL ZL XL.
